Global Muscle Relaxant Drugs Market 2017-2021
SKU ID :TNV-10359368 | Published Date: 07-Mar-2017 | No. of pages: 70Description
TOC
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Key market highlights
PART 05: An overview of muscle spasticity and spasms
PART 06: Pipeline landscape
PART 07: Market landscape
• Market overview
• Five forces analysis
PART 08: Market segmentation by product category
• Skeletal muscle relaxant drugs
• Facial muscle relaxant drugs
PART 09: Geographical segmentation
• Muscle relaxant drugs market in Americas
• Muscle relaxant drugs market in EMEA
• Muscle relaxant drugs market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
• Market drivers
• Impact of drivers on key customer segments
• Market challenges
• Impact of challenges on key customer segments
PART 12: Market trends
• Anti-aging treatments driving adoption of facial relaxants
• Advanced drug delivery technologies fuels adoption of muscle relaxants
• Growing use of muscle relaxants in new indications and applications
PART 13: Vendor landscape
• Competitive scenario
PART 14: Key vendor analysis
• Pfizer
• Allergan
• Ipsen Group
• Teva Pharmaceuticals
• Novartis
• Other prominent vendors
PART 15: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Key muscle relaxants
Exhibit 02: Pipeline landscape
Exhibit 03: Global muscle relaxant drugs market snapshot
Exhibit 04: Global muscle relaxant drugs market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis in global muscle relaxant drugs market
Exhibit 06: Five forces analysis
Exhibit 07: Global muscle relaxant drugs market by product category 2016
Exhibit 08: Global skeletal muscle relaxant drugs market 2016-2021 ($ millions)
Exhibit 09: Global facial muscle relaxant drugs market 2016-2021 ($ millions)
Exhibit 10: Global muscle relaxant drugs market by geography 2016 and 2021
Exhibit 11: Global muscle relaxant drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 12: Market scenario in Americas
Exhibit 13: Muscle relaxant drugs market in Americas 2016-2021 ($ millions)
Exhibit 14: Market scenario in EMEA
Exhibit 15: Muscle relaxant drugs market in EMEA 2016-2021 ($ millions)
Exhibit 16: Market scenario in APAC
Exhibit 17: Muscle relaxant drugs market in APAC 2016-2021 ($ millions)
Exhibit 18: Key approvals for new indications
Exhibit 19: Key factors driving the market growth
Exhibit 20: Impact of drivers
Exhibit 21: Impact of challenges
Exhibit 22: Competitive structure analysis of global muscle relaxant drugs market 2016
Exhibit 23: Competitive analysis of global muscle relaxant drugs market
Exhibit 24: Strategic success factors of companies in global muscle relaxant drugs market
Exhibit 25: Pfizer: Strength assessment
Exhibit 26: Pfizer: Strategy assessment
Exhibit 27: Pfizer: Opportunity assessment
Exhibit 28: Allergan: Key highlights
Exhibit 29: Allergan: Strength assessment
Exhibit 30: Allergan: Strategy assessment
Exhibit 31: Allergan: Opportunity assessment
Exhibit 32: Ipsen Group: Key highlights
Exhibit 33: Ipsen Group: Strength assessment
Exhibit 34: Ipsen Group: Strategy assessment
Exhibit 35: Ipsen Group: Opportunity assessment
Exhibit 36: Teva Pharmaceuticals: Strength assessment
Exhibit 37: Teva Pharmaceuticals: Strategy assessment
Exhibit 38: Teva Pharmaceuticals: Opportunity assessment
Exhibit 39: Novartis: Strength assessment
Exhibit 40: Novartis: Strategy assessment
Exhibit 41: Novartis: Opportunity assessment
Tables & Figures
Companies
Pfizer, Ipsen Group, Allergan, Novartis, Teva Pharmaceuticals, Acorda Therapeutics, Aldeyra Therapeutics, Canbex Therapeutics, Daewoong, Emcure Pharmaceuticals, Endo International, Fresenius Kabi, Galderma, INSYS Therapeutics, Johnson & Johnson, Lannett Company, Merz Pharma, Mylan, Par Pharmaceutical, PhytoTech Therapeutics, Revance Therapeutics, Sun Pharmaceutical Industries, and Takeda Pharmaceutical.
- PRICE
-
$2500$4000